TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24114421
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light therapy (IPL)
Study: 15823625
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor moexipril added to combination therapy
Study: 2045727
Drug: Methylphenidate (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (three levels of dosage)
Study: 6768443
Drug: Thiotepa weekly
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Thiotepa weekly for one year (N = 90)
Study: 6768443
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy (Control group, N = 77)
Study: 6768443
Drug: Thiotepa treatment
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Thiotepa treatment in negative node patients less than 55 years old
Study: 25521726
Drug: Teprenone 150
Normalized name: teprenone
DrugBank: Teprenone (DB15955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teprenone 150 mg/day
Study: 17889680
Drug: Slow injection
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow injection (2.0 mL lidocaine with 1:80,000 epinephrine over 60 seconds)
Study: 17889680
Drug: Rapid injection
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid injection (2.0 mL lidocaine with 1:80,000 epinephrine over 15 seconds)
Study: 9205762
Drug: Ebrotidine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine 400 mg daily
Study: 9205762
Drug: Ebrotidine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine 600 mg daily
Study: 9205762
Drug: Ebrotidine 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine 800 mg daily
Study: 9205762
Drug: Ebrotidine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebrotidine 200 mg daily
Study: 7963150
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray (2 sprays per nostril once daily)
Study: 3598772
Drug: 64 kcal/kg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 64 kcal/kg/d nonprotein energy plus 1 to 2 g/kg/d crystalline amino acids (Group 3)
Study: 26764260
Drug: Disease activity-guided
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disease activity-guided dose optimisation strategy of adalimumab or etanercept (TNFi)
Study: 22542362
Drug: Eculizumab therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab therapy
Study: 18317625
Drug: Low-calorie diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calorie diet plus orlistat 120 mg three times daily
Study: 14722733
Drug: Tamoxifen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (40 mg/day)
Study: 10333912
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus repaglinide
Study: 10333912
Drug: Repaglinide (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (combined therapy)
Study: 10333912
Drug: Repaglinide (monotherapy)
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide (monotherapy)
Study: 10333912
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (metformin and repaglinide)
Study: 7793116
Drug: Continuous s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous s.c. infusion of AVP (7.5 micrograms/d) for one week
Study: 7793116
Drug: 0.9% NaCl-solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl-solution (placebo)
Study: 2025476
Drug: Propofol 6
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 6 mg kg‐1 h‐1 after 90 min of nitrous oxide 66% in oxygen
Study: 7344590
Drug: Acebutolol 400mg
Normalized name: acebutolol 400 MG
DrugBank: Acebutolol (DB01193)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acebutolol 400mg or more daily (once daily dosing)
Study: 7344590
Drug: Acebutolol 400mg
Normalized name: acebutolol 400 MG
DrugBank: Acebutolol (DB01193)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acebutolol 400mg or more daily (twice daily dosing)
Study: 28241159
Drug: Bright Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright Light Therapy (LT)
Study: 28241159
Drug: Dim-Red Light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim-Red Light Therapy (Control)
Study: 19350472
Drug: Experimental add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental add-on therapy with D-Cycloserine
Study: 14985175
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine intake (300-350 ml, approximately two glasses)
Study: 14985175
Drug: White wine
Normalized name: White wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: White wine intake (300-350 ml, approximately two glasses)
Study: 3898645
Drug: Psychological biobehavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological biobehavioral treatment program
Study: 30350844
Drug: Policosanol +
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol + aspirin
Study: 22608359
Drug: CoQ10 60
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 60 mg twice daily
Study: 15319673
Drug: Enfuvirtide (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enfuvirtide (90 mg twice daily) + optimized background regimen
Study: 11921421
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg daily
Study: 1362671
Drug: Pen injector
Normalized name: Pen Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pen injector (Human NPH insulin in penfills)
Study: 1362671
Drug: Syringe (Human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syringe (Human NPH insulin in vials)
Study: 3516754
Drug: Hydrocortisone 17-butyrate
Normalized name: Cortisol 17-butyrate
DrugBank: Hydrocortisone butyrate (DB14540)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrocortisone 17-butyrate (Locoid) 0.1% fatty cream
Study: 3516754
Drug: Desonide (Apolar)
Normalized name: Desonide
DrugBank: Desonide sodium phosphate (DB15835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desonide (Apolar) 0.1% ointment
Study: 30865051
Drug: Daily dosing
Normalized name: Osmolex 322 MG Daily Dosing Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing arm of FTC/TDF-based PrEP
Study: 26510664
Drug: Clostridium butyricum
Normalized name: Clostridium butyricum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clostridium butyricum MIYAIRI (CBM) - 9 tablets orally once daily
Study: 26510664
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 9 tablets orally once daily
Study: 11472321
Drug: Ecabet sodium
Normalized name: ecabet sodium
DrugBank: Ecabet (DB05265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecabet sodium 1 g b.d., amoxicillin 500 mg t.d.s. and clarithromycin 400 mg b.d. (EAC)
Study: 11472321
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg (o.m.) with the same antimicrobial agents (LAC)
Study: 7842354
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (1,000 mg/day for 2 weeks)
Study: 7842354
Drug: Inert inositol
Normalized name: inert ingredients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert inositol tablets (control)
Study: 2896383
Drug: Trimoprostil (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimoprostil (3 mg daily for 4 weeks)
Study: 12381251
Drug: Pantoprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (20 mg once daily)
Study: 10480346
Drug: Humanized antibody
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Humanized antibody against HER2 (Herceptin)
Study: 10480346
Drug: Humanized antibody
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Humanized antibody against HER2 (Herceptin) combined with chemotherapy
Study: 8548972
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% lignocaine ointment
Study: 28718049
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin using a handheld, battery-operated, breath-actuated inhaler with aerosol generators producing 3-6 μm particle size distribution.
Study: 28718049
Drug: Inhaled insulin
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled insulin with inspiratory flow of 10 L/min guided by LED.
Study: 25497721
Drug: Low fibrinogen
Normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fibrinogen group (fibrinogen levels < 2 g/L or decreased by 25% or more)
Study: 21379417
Drug: Artemether plus
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether plus lumefantrine (A+L)
Study: 21379417
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with chloroquine plus sulfadoxine plus pyrimethamine (CQ+S+P)
Study: 19910721
Drug: Atomoxetine (ATM)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATM) 40-100 mg per day, n = 14
Study: 17908591
Drug: CAT-152 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAT-152 (100 microg in 100 microl phosphate buffer) administered via 4 subconjunctival injections before and after trabeculectomy and at 1 week post-surgery.
Study: 17908591
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via 4 injections before and after trabeculectomy and at 1 week post-surgery.
Study: 14961887
Drug: Duloxetine 40
Normalized name: duloxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 40 mg BD for 12 weeks
Study: 9241341
Drug: 2-Chloroprocaine (2-CP)
Normalized name: 2-chloroprocaine
DrugBank: Chloroprocaine (DB01161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-Chloroprocaine (2-CP) + epinephrine (Epi, 5 micrograms.ml-1)
Study: 8363422
Drug: APSAC (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: APSAC (30 mg i.v. over 5 minutes)
Study: 8363422
Drug: rt-PA (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA (10 mg bolus + 5000 IU of heparin as a bolus, followed by 90 mg rt-PA over 3 hours)
Study: 3097293
Drug: L-carnitine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (50 mumol/kg/day)
Study: 31378383
Drug: Combination (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (1 g paracetamol, 400 mg ibuprofen, 60 mg codeine)
Study: 28331155
Drug: Celecoxib monotherapy
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib monotherapy (NSAID group)
Study: 21598207
Drug: Occupational group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational group therapy, performed regularly 6 days a week
Study: 9184950
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (standard protocol by continuous infusion)
Study: 3297376
Drug: Alizapride (AZP)
DrugBank: Alizapride (DB01425)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alizapride (AZP) 2 mg/kg for 4 doses
Study: 3297376
Drug: Alizapride (AZP)
DrugBank: Alizapride (DB01425)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alizapride (AZP) 2 mg/kg for 4 doses + Dexamethasone (DXM) 8 mg for five doses
Study: 3297376
Drug: Metoclopramide (MCP)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MCP) 1 mg/kg for four doses + Dexamethasone (DXM) 8 mg for five doses
Study: 25422488
Drug: Doxorubicin-cyclophosphamide administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-cyclophosphamide administered continuously
Study: 25422488
Drug: Paclitaxel administered
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel administered once per week
Study: 25422488
Drug: Doxorubicin-cyclophosphamide administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-cyclophosphamide administered once every 2 weeks
Study: 25422488
Drug: Paclitaxel administered
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel administered once every 2 weeks
Study: 21515996
Drug: Integrated care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated care service (n=36) including physical therapy, acupuncture, western medicines or herbal medicines
Study: 21515996
Drug: Western care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western care (n=49) including physical therapy or western medicines
Study: 19630713
Drug: Pharmacological aids
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological aids (e.g., nicotine replacement therapy, bupropion)
Study: 16963397
Drug: Long-term follow-up
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term follow-up after completion of therapy
Study: 9589359
Drug: Retinamide II
Normalized name: retinamide
DrugBank: Retinamidic acid (DB17418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinamide II (RII) suppositories, 10 mg QD, given intravaginally for 6 months (each course lasting 3 months)
Study: 9589359
Drug: Retinamide II
Normalized name: retinamide
DrugBank: Retinamidic acid (DB17418)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinamide II (RII) suppository intravaginally, once daily for 50 days in two courses
Study: 9589359
Drug: Placebo, once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, once daily for 50 days in two courses
Study: 30880777
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1000 mg/day) for 4 weeks
Study: 19375954
Drug: Full preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full preparation (2-L polyethylene glycol solution with 20 mL of sodium diatrizoate)
Study: 19375954
Drug: Minimum preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimum preparation (45 mL of sodium diatrizoate and 10 mL of sodium picosulfate solution)
Study: 19375954
Drug: Full preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full preparation
Study: 19375954
Drug: Minimum preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimum preparation
Study: 10682564
Drug: Fraxiparine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fraxiparine (0.4 ml hypodermically injected per day for 7 days)
Study: 8583438
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate (Fleet PhosphoSoda)
Study: 8583438
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol electrolyte (PEG) solution (GoLYTELY)
Study: 632455
Drug: .3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: .3 mg/kg of Ritalin
Study: 31462288
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy regimens (specific regimens not detailed)
Study: 31462288
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy for patients with weight loss ≥10% at baseline
Study: 28075381
Drug: n-3 PUFAs
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFAs (480 mg DHA and 720 mg EPA per day)
Study: 23623474
Drug: Etonogestrel-releasing implant
Normalized name: etonogestrel Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etonogestrel-releasing implant
Study: 20430565
Drug: Counseling programs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counseling programs with advice about nicotine replacement therapy (and additional bupropion‐SR in one of the programs)
Study: 19644802
Drug: Etofibrate 1000
Normalized name: etofibrate
DrugBank: Etofibrate (DB08983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etofibrate 1000 mg/day for up to 12 months
Study: 3383611
Drug: Controlled-release naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release naproxen (750 mg)
Study: 3383611
Drug: Standard naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard naproxen (750 mg)
Study: 28243834
Drug: Sodium Tanshinone
Normalized name: Tanshinone I
DrugBank: Tanshinone I (DB16886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Tanshinone IIA Sulfonate (STS) 60 mg/day
Study: 25756440
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (fracture fixation or humeral head replacement)
Study: 25756440
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment (sling immobilization)
Study: 24690891
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 4 ml/kg
Study: 21597111
Drug: High concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration oxygen (8 l/min via medium concentration mask)
Study: 16580376
Drug: Ovarian stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian stimulation with rhLH (150 IU daily) and rhFSH
Study: 10690979
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 100 mg suppositories for 21 days
Study: 10690979
Drug: Placebo suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppositories for 21 days
Study: 9176035
Drug: L-lysine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-lysine infusion
Study: 2809781
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone (0.25 mg/kg)
Study: 31594919
Drug: Pomalidomide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (4 mg daily for 21 days every 4 weeks) and dexamethasone (40 mg weekly)
Study: 31594919
Drug: Pomalidomide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (4 mg daily for 21 days every 4 weeks) and dexamethasone (40 mg weekly) + cyclophosphamide (300 mg/m2 if less than minimal response after three cycles)
Study: 31594919
Drug: Pomalidomide and
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide and dexamethasone combination
Study: 31594919
Drug: Pomalidomide and
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide and dexamethasone combination with cyclophosphamide
Study: 19397474
Drug: low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: low sodium + 100mg losartan + 25 mg hydrochlorothiazide
Study: 17142656
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 0.5 mg·kg-1 po administered 20-30 min preoperatively
Study: 8617997
Drug: 1 alpha,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 alpha,25(OH)2D3 (15 microgram/g Vaseline)
Study: 1958442
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release nicotinic acid formulation (500 mg)
Study: 1958442
Drug: Rapid-release nicotinic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-release nicotinic acid formulation (500 mg)
Study: 7082061
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia (PCA) device with intravenous morphine sulfate
Study: 7082061
Drug: Standard intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intramuscular dosages of morphine sulfate
Study: 7082061
Drug: Morphine usage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine usage in PCA group
Study: 19563061
Drug: Yasmin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yasmin (30 microg ethinylestradiol plus 3 mg drospirenone)
Study: 11605110
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (local anesthesia)
Study: 11907935
Drug: Conpremin (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conpremin (0.625 mg tablets)
Study: 11907935
Drug: Generic conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic conjugated estrogens (0.625 mg tablets)
Study: 7862712
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg cocaine IV on day 1, 25 mg cocaine IV on day 2
Study: 7862712
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion on day 1, saline infusion on day 2
Study: 31832992
Drug: Buccal infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal infiltration (BI) using 4% articaine
Study: 18033629
Drug: Daily 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 10 mg alendronate and calcium
Study: 18033629
Drug: Every other
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every other day 10 mg alendronate and calcium
Study: 18033629
Drug: Daily 200
Normalized name: Culturelle Probiotics Digestive Daily 200mg-10 Billion CFU Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 200 IU calcitonin and calcium
Study: 11322350
Drug: Extended-release oxybutynin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release oxybutynin, 10 mg/d
Study: 24895382
Drug: Hydrotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrotherapy treatment
Study: 9408932
Drug: Land treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Land treatment
Study: 2878746
Drug: Insulin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (0.1 IU/kg body weight)
Study: 31240998
Drug: Computerized WCST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized WCST administration